950 — Lees Pharmaceutical Holdings Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapSuper Stock

Annual income statement for Lees Pharmaceutical Holdings, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	HKAS	HKAS	HKAS	HKAS	HKAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,217	1,266	1,233	1,053	1,400
Cost of Revenue
Gross Profit	781	806	771	551	753
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,065	-712	1,157	1,009	1,287
Operating Profit	152	1,979	76.6	43.6	113
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	134	1,969	67.9	30.8	98.1
Provision for Income Taxes
Net Income After Taxes	78.5	1,960	45.8	19.9	68.6
Minority Interest
Net Income Before Extraordinary Items
Net Income	129	1,987	51.3	16.7	93.1
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	129	1,987	51.3	16.7	93.1
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.25	1.07	0.09	0.019	0.177
Dividends per Share